Union Bancaire Privee UBP SA Acquires New Shares in Edwards Lifesciences Co. (NYSE:EW)

Union Bancaire Privee UBP SA purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 14,802 shares of the medical research company's stock, valued at approximately $1,120,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Bowman & Co S.C. raised its position in Edwards Lifesciences by 1.2% in the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company's stock valued at $924,000 after buying an additional 148 shares during the last quarter. JFS Wealth Advisors LLC grew its position in Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock worth $46,000 after purchasing an additional 166 shares in the last quarter. Seascape Capital Management increased its stake in Edwards Lifesciences by 0.5% in the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company's stock valued at $2,177,000 after buying an additional 174 shares during the last quarter. Cooper Financial Group lifted its position in shares of Edwards Lifesciences by 2.8% during the 4th quarter. Cooper Financial Group now owns 6,466 shares of the medical research company's stock worth $479,000 after buying an additional 175 shares in the last quarter. Finally, Martin Capital Advisors LLP boosted its stake in shares of Edwards Lifesciences by 0.7% in the 3rd quarter. Martin Capital Advisors LLP now owns 25,546 shares of the medical research company's stock worth $1,686,000 after buying an additional 186 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

NYSE EW traded up $3.32 during trading on Tuesday, reaching $72.52. The company's stock had a trading volume of 7,623,827 shares, compared to its average volume of 4,757,949. The stock has a market capitalization of $42.77 billion, a PE ratio of 10.46, a P/E/G ratio of 3.54 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a fifty day moving average of $72.32 and a 200 day moving average of $70.19. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Wall Street Analyst Weigh In

EW has been the topic of several research analyst reports. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $63.00 to $68.00 and gave the stock a "hold" rating in a research report on Thursday, December 5th. Truist Financial reissued a "hold" rating and issued a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Wolfe Research downgraded shares of Edwards Lifesciences from a "peer perform" rating to an "underperform" rating and set a $60.00 price objective for the company. in a report on Thursday, January 16th. Bank of America upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and boosted their target price for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Finally, Piper Sandler decreased their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a "neutral" rating for the company in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of "Hold" and a consensus target price of $78.48.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares of the company's stock, valued at $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company's stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,000 shares of company stock valued at $2,195,180 over the last three months. 1.29% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.